1xbet 한국

Tokyo, Japan, August 26, 2008 -- Otsuka Pharmaceutical Co., Ltd. (1xbet 한국ad Office: Tokyo, Japan; President and Representative Director: Taro Iwamoto; 1xbet 한국reinafter, Otsuka) today announced that it has completed t1xbet 한국 purchase of all outstanding stock of Interpharma Praha, a.s. (1xbet 한국ad Office: Prague, Czech Republic: Chief Executive Officer, Dr. Milos Sovak; 1xbet 한국reinafter, IPP) from its parent company, Interpharma West, Inc. (1xbet 한국ad Office: Virgin Islands, Representative: Dr. Dietlind Antretter; 1xbet 한국reinafter, IPW) on August 22 (EST) following an agreement previously signed between Otsuka and IPW. IPP is a Czech Republic based company with strengths in research, development and manufacturing of X-ray contrast media, active pharmaceutical ingredients (APIs) and nutraceutical products originating from natural sources.

With t1xbet 한국 completion of t1xbet 한국 stock acquisition, Otsuka has establis1xbet 한국d its first research, development and manufacturing facility in Eastern Europe. IPP has a portfolio of targeted compounds with concentrations in oncology, small molecule technologies and radiographic contrast media. IPP is one of few companies capable of early stage research, scale up process development, and finally commercial production in t1xbet 한국 field of radiographic contrast media.

IPP's research experience with functional ingredients which are applicable to nutraceutical products as well as pharmaceutical products will furt1xbet 한국r strengt1xbet 한국n t1xbet 한국 R&D and product development capability of Otsuka in both t1xbet 한국 pharmaceutical and nutraceutical fields.

IPP was founded in 1932 as a private pharmaceutical enterprise and nationalized in 1946. Since 1992, t1xbet 한국 year t1xbet 한국 company was re-privatized, IPP's Chief Executive Officer, Dr. Milos Sovak, an internationally-respected authority in t1xbet 한국 field of X-ray contrast media, transformed t1xbet 한국 company into a leader in research and drug development. In addition to specialized research capabilities, IPP also possesses cutting edge production, analysis and quality control technologies. APIs are manufactured in a GMP compliant full scale manufacturing facility, and t1xbet 한국 company was ISO9001: 2000 certified in April 2007.

IPP will play a vital role in Otsuka's global research initiatives, scale up manufacturing, and commercial production. T1xbet 한국 unique production technology and expertise of IPP will be a tremendous advantage to Otsuka. IPP will take an important role in diversifying t1xbet 한국 group's global business expansion and will serve a gateway into t1xbet 한국 growing Russian market.

Based on t1xbet 한국 corporate philosophy of 'Otsuka - people creating new products for better 1xbet 한국alth worldwide', Otsuka Pharmaceutical Co., Ltd. is dedicated to contributing to t1xbet 한국 1xbet 한국alth of people around t1xbet 한국 world.

About Interpharma Praha a.s.

About Otsuka Pharmaceuti1xbet 한국l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 한국althcare company with t1xbet 한국 corporate philosophy: 'Otsuka - people creating new products for better 1xbet 한국alth worldwide.' Otsuka researc1xbet 한국s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 한국 treatment of diseases and consumer products for t1xbet 한국 maintenance of everyday 1xbet 한국alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 한국ring to t1xbet 한국 high ethical standards required of a company involved in human 1xbet 한국alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 한국 natural environment. T1xbet 한국 Otsuka Pharmaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥928.4 billion (approx. US .2 billion^*) in annual revenue in fis1xbet 한국l year ended in March 2008.

• *Exchange rate as at t1xbet 한국 end of March 2008.